THE CARE CONVERSATION
Bring questions.
Get clear answers.
Put your main goal and your questions in a note. Leave room for the answers.
?
WHEN A FORM FALLS SHORT
A visit needs room for a conversation.
Choosing medicine from a list alone falls short of proper care standards, says the Federation of State Medical Boards in guidance checked September 26, 2026.
It calls for a review of your health; filling out an unchanging online form cannot meet that need on its own.
The same group says you must be able to ask questions of your doctor or other health professional after the visit.
Its advice helps state boards set rules; each state decides which rules have legal force.
For the rules that apply to your visit, contact the medical board for the state you’ll be in at the time.
The health professional who can order medicine is called a prescriber.
QUESTIONS TO BRING
Pin down the product, the review and the follow-up.
Which medicine, and for what goal?
As of September 26, 2026, semaglutide (Wegovy) had U.S. approval for reducing excess weight and keeping it off.
For adults who have type 2 diabetes, semaglutide (Ozempic) was approved to help manage blood sugar.
For certain adults with type 2 diabetes, Ozempic also had approvals to lower heart attack and stroke risk and slow kidney disease.
Weight management means reducing excess weight and keeping the loss over time.
Under U.S. rules checked September 26, 2026, an approved drug could be prescribed off-label, for a purpose outside its approved uses.
Ask why the proposed product fits your goal and whether insurance covers that use.
How does my health history affect the choice?
Bring your medicine list. Include health conditions, past allergic reactions and pregnancy plans.
The semaglutide label asks prescribers to review these parts of your health history.
- A history of thyroid cancer, whether yours or a family member’s; the label warns about neck lumps in this body part.
- Pancreas trouble: painful swelling of that body part, linked in the label to lasting belly pain that may spread to the back.
- Gallbladder trouble, such as gallstones, meaning stones in that body part.
- Severe stomach problems, eye damage from diabetes, or surgery coming up.
If those names are unfamiliar, bring the names of past illnesses or operations from your records. Ask the prescriber to go through them with you.
Ask whether your history calls for tests or an exam, and how those would be arranged.
Who answers me after the visit?
Ask how to reach the prescriber, how new symptoms are handled, and when the next review happens.
For telehealth, care given from a distance, ask what happens if an in-person exam is needed.
Ask for the pharmacy’s name, too. You can use the medicine and licence checks to follow up.
PUT RESULTS IN CONTEXT
Talk about likely results.
STEP 1 studied adults without diabetes who had obesity or had excess weight along with a related health problem.
At 68 weeks, average body-weight loss was 14.9% for people given semaglutide and 2.4% for those given a shot containing no active medicine.
Both groups received help with diet and activity, and individual results varied.
Ask about the months after treatment.
Over the year after treatment ended, the STEP 1 follow-up group regained roughly two-thirds of its earlier weight loss.
Ask what ongoing care would involve, what it would cost, and how a decision to stop would be reviewed.
NEXT QUESTIONWhat will the whole care plan cost?→
THE SOURCE NOTES
See what backs these answers.
Read the original guidance, records and research.
Open this page’s sources +